glp-1 advertising policy news Fmr. FDA Commissioner weighs in on Medicare's involvement in prices The GLP-1 Era Invites Brands

Incorporating strategies like reminders or syncing injections with daily habits can further enhance adherence, ensuring you stay on track with your treatment plan

But insulin dose reduction needs to be done carefully and gradually, with close CGM monitoring, to avoid either hypoglycemia (from too much insulin relative to your new needs) or hyperglycemia (from reducing too aggressively)

-No effect on brain mechanism

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R)

Membership promotion: According to the company's website, Ivim Health currently offers the first month of membership at no additional cost

India became one of the first major markets to see generic launches after Novo Nordisks core patent on the molecule expired there in March 2026